A federal health care program meant to aid hospitals serving impoverished patients provides little benefit to the public while serving as a “slush fund” for health systems that promote woke ideology, a conservative advocacy group argues.
Heartland Impact rolled out a digital campaign on Thursday urging lawmakers to reform a federal program that makes drug manufacturers sell their drugs for discounted rates to certain health systems serving poor patients. Critics say the program, known as 340B Drug Pricing, lacks guardrails to ensure the benefits are passed on to patients and it doesn’t just pad the wallets of bloated hospital systems.
The campaign, first shared with The Daily Wire, targets Minnesota’s Mayo Clinic system as a beneficiary of the program and criticizes it for paying executives hefty salaries and pushing DEI and transgender ideology.
“As a participant in the 340B program, Mayo Clinic should prioritize charity care, not subsidize woke initiatives, pro-sports sponsorships, and executive perks, all while pursuing aggressive debt collection against patients,” Heartland Impact executive director Cameron Sholty told The Daily Wire. “Without reform, 340B will continue fueling corporate excess and waste while patients pay the price.”
Institutions within the Mayo Clinic, a tax-exempt nonprofit health system, benefit from participation in the 340B program, including one in Albert Lea, Minnesota, which reported $8.9 million in net revenue in 2024 linked to the program, according to a state report.
The Daily Wire reached out to Mayo Clinic for comment on the campaign.
Heartland Impact’s campaign highlights Mayo’s partnership with Minnesota’s professional NBA and WNBA basketball teams and the seven-figure salaries given to top executives. Mayo has also pushed climate activism and rebranded its DEI office as the “Office of Belonging.”
The campaign highlights Mayo’s Transgender and Intersex Specialty Care Clinic, which offers procedures such as surgeries to carve up a gender-confused man’s face to make it look more feminine, genital procedures, and removing the breasts of gender-confused women through a “masculinization surgery.” The clinic also offers puberty blockers for “gender-diverse youth” to stop healthy development.
Mayo, which reported $21.5 billion in revenue in 2025, has faced criticism for providing low rates of charity care. Charity care is the free or discounted health care provided to uninsured or low-income patients that hospitals must provide to maintain their tax-exempt status.
In both 2024 and 2025, less than 1% of Mayo’s revenue went toward charity care. That rate was significantly lower than comparable systems, which often designate at least 2% of their expenses for charity care.
A March 225 settlement between Mayo and Minnesota required the health system to agree not to sue to collect medical debt in other than extraordinary circumstances and expand its charity care process. That settlement came after a report that the system sued patients eligible for charity care over debt collection.
“While the 340B drug program was created to help rural hospitals or reduce drug costs for patients, it’s become a slush fund for large corporate hospital systems like Mayo Clinic,” the narrator of the Heartland Impact campaign says. “Since 2022, non-profit Mayo Clinic received nearly $2 billion from taxpayers, while Tiny-‘Tim-ing’ patients who qualify for charity care with aggressive debt collection practices like lawsuits and wage garnishment.”
In previous testimony, Sholty argued that the 340B program has ballooned far beyond its original purpose and allowed giant hospital systems with limited charity-care obligations to benefit from it.
Some Republicans have long been critical of the 340B program and called for reforms. Last year, Reps. Buddy Carter (R-GA) and Diana Harshbarger (R-TN) put forth a bill to update the program to ensure it was operating as intended. A report from the Senate Health, Education, Labor, and Pensions Committee called for similar reforms.


